We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

BASF licenses CRISPR-Cpf1 from the Broad Institute of MIT and Harvard

News   Oct 26, 2018 | Original Press Release from BASF

 
BASF licenses CRISPR-Cpf1 from the Broad Institute of MIT and Harvard

BASF technicians in a white biotechnology research lab in Germany are working with microorganisms to produce enzymes. Credit: BASF

 
 
 

RELATED ARTICLES

New Material Could Drive Wound Healing

News

Imperial researchers have developed a new bioinspired material that interacts with surrounding tissues to promote healing.

READ MORE

World’s First Genetically Enhanced Human Vascular Cells

News

Scientists have generated the world's first genetically enhanced human vascular cells by targeting a single longevity gene, FOXO3.

READ MORE

‘Shortcut’ Transforms Terpene Biosynthesis in E. Coli

News

Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE